Spots Global Cancer Trial Database for Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
Official Title: A Phase 1/2 Study Of Cmc-544 Administered In Combination With Rituximab In Subjects With Follicular Or Diffuse Large B-cell Non-hodgkin's Lymphoma
Study ID: NCT00299494
Conditions
Study Description
Brief Summary: The purpose of the study is to determine the tolerability, the initial safety profile and maximum tolerated dose, and to obtain preliminary information on the antitumor activity of inotuzumab ozogamicin \[CMC-544\] in combination with rituximab in subjects with follicular, diffuse large B-Cell, or mantle cell NHL.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham-, Birmingham, Alabama, United States
IDS Pharmacy, Birmingham, Alabama, United States
University of Alabama at Birmingham-, Birmingham, Alabama, United States
California Cancer Care, Inc., Greenbrae, California, United States
University of California Medical Center, San Francisco, California, United States
California Cancer Care, San Mateo, California, United States
Emory Clinic, Atlanta, Georgia, United States
Emory University Hospital, Atlanta, Georgia, United States
Emory University Investigational Drug Service, Atlanta, Georgia, United States
Northwestern Medical Faculty Foundation, Chicago, Illinois, United States
Nevada Cancer Institute-, Las Vegas, Nevada, United States
Rosewell Park Cancer Institute, Buffalo, New York, United States
Gabrail Cancer Center, Canton, Ohio, United States
University Hospitals of Cleveland, Cleveland, Ohio, United States
Cleveland Clinic, Cleveland, Ohio, United States
Gabrail Cancer Center, Dover, Ohio, United States
UHHS - Westlake, Westlake, Ohio, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Royal Brisbane and Women's Hospital, Herston, Brisbane, QLD, Australia
Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, Vlaams-brabant, Belgium
Universitair Ziekenhuis Gent, Gent, , Belgium
University Hospital Gent - Department of Hematology, Gent, , Belgium
Hôpital André MIGNOT, Le Chesnay, , France
Hôpital Saint-Louis, Paris, , France
CH Lyon Sud, Pierre Benite, , France
Universitaetsklinik Bonn, Medizinische Klinik und Poliklinik III, Bonn, , Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet, III. medizinische klinik und Poliklinik, Mainz, , Germany
Prince Of Wales Hospital, Shatin N.T., , Hong Kong
Universita La Sapienza Cattedra di Ematologia, Roma, , Italy
Asan Medical Center, Seoul, , Korea, Republic of
Erasmus Medisch Centrum--, Rotterdam, Zuid-holland, Netherlands
Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warszawa, , Poland
Hospital Clinic I Provincial de Barcelona, Barcelona, , Spain
University Hospital Zurich, Zurich, , Switzerland
Derriford Hospital - Plymouth, Plymouth, Devon, United Kingdom
Somers Cancer Science Building MP824, Southampton, Hampshire, United Kingdom
Bart's Cancer Institute; Queen Mary University of London, London, , United Kingdom
Contact Details
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
